Volume 10, Number 1Review ArticlesCurrent Medical Therapies for Men With Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: Achievements and LimitationsTreatment UpdateClaus G RoehrbornOver the last 20 years, our understanding of the pathophysiology and symptomatology of men with lower urinary tract symptoms (LUTS) has become increasingly more sophisticated. With this increase in sophistication, our utilization of various medical therapies, either alone or in combination, has also increased the understanding of the roles of individual medications, combinations of medications, and the benefits of different types of intervention. The rapid decline of the use of transurethral resection of the prostate (TURP) and other surgical procedures for benign prostatic hyperplasia (BPH) in the 1990s is due in part to the introduction of medical therapy. This article reviews the current state of medical therapy for men with LUTS and highlights its promises and its current limitations. [Rev Urol. 2008;10(1):14-25]Benign prostatic hyperplasiaMedical therapy5-Alpha-reductase inhibitorsLower urinary tract symptomsAlpha-adrenergic receptor blockers
Volume 21, Number 4Review ArticlesLong-term Consequences of Medical Therapy for Benign Prostatic HyperplasiaManagement UpdateEric M BortnickVannita Simma-ChiangSteven A KaplanBenign prostatic hyperplasia (BPH) is a common disease in men. Although transurethral resection of the prostate (TURP) is the gold standard therapy for treatment of BPH and associated lower urinary tract symptoms (LUTS), many patients choose to avoid surgery and instead choose medical therapy. Until recently, medical therapy for BPH has been thought to be both safe and effective. However, new studies have shown that some of these medications can have significant neurocognitive, psychiatric, and sexual side effects, including dementia and depression. As most patients taking these medications will continue them for the long term, it is vital for physicians to explain these potential risks to the patient prior to prescribing them for a quality-of-life condition. [Rev Urol. 2019;21(4):154–157] © 2020 MedReviews®, LLCBenign prostatic hyperplasiaMedical therapyDepressionDementia5-Alpha-reductase inhibitorsalpha-blockers